Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches.

Cancers (Basel) · 2026 · PMC13024755 · PMID 41899581

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

The EMERALD-1 trial showed that the addition of durvalumab (anti-PD-L1) and bevacizumab to TACE significantly extended progression-free survival compared with TACE alone (15.0 versus 8.2 months; HR 0.77, p = 0.032), successfully meeting the primary endpoint and demonstrating a strong trend toward overall survival improvement [ 93 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.